Rodan + Fields' President and CEO spoke with HBW Insight about the company’s push to build an omnichannel ecosystem and what ...

A biosimilar request for approval can arrive four to six months, and be reviewed, before the earliest lawful approval date, ...

Shea joined the agency in April 2025 and helped oversee the consolidation of HR, IT and other functions into the Office of Operations.

ADARx, the 22nd drug developer to go public in the US in 2026, closed its first day up 13.8% from its IPO price. Also, Viking ...

Detailed Phase III data for JAK3/TEC inhibitor Litfulo (ritlecitinib) in nonsegmental vitiligo were presented at EADV. Pfizer ...

A key piece of Sandoz’s ‘Bio100’ strategy has fallen into place with the opening of a major biosimilars manufacturing plant ...

After J&J’s Janssen succeeded in obtaining a US injunction preventing Accord and Bio-Thera from launching their FDA-approved ...

A UK ruling that Eli Lilly breached industry Code of Practice for a press release and new Australian guidance on media ...

Now that we are trying to complete and devise some efforts about how to follow those requirements, it's sometimes being ...

California's top court refused to hold Gilead liable for delaying a safer HIV drug to protect its franchise – a win for ...

The FDA selected three more technologies for its READI-Home Innovation Challenge, including home blood collection from Becton ...

Amid ongoing geopolitical complexities and “profound transformations” affecting the pharmaceutical industry, French ...